Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $4.6 million.

  • Orchestra BioMed Holdings' Current Deferred Revenue rose 1433.84% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 1433.84%. This contributed to the annual value of $4.4 million for FY2024, which is 7685.26% up from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Current Deferred Revenue stood at $4.6 million, which was up 1433.84% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Current Deferred Revenue registered a high of $18.5 million during Q1 2023, and its lowest value of $2.5 million during Q4 2023.
  • For the 4-year period, Orchestra BioMed Holdings' Current Deferred Revenue averaged around $5.3 million, with its median value being $4.2 million (2023).
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Current Deferred Revenue was 7685.26% (2024), while the steepest drop was 8341.79% (2024).
  • Orchestra BioMed Holdings' Current Deferred Revenue (Quarter) stood at $6.4 million in 2022, then plummeted by 61.0% to $2.5 million in 2023, then surged by 76.85% to $4.4 million in 2024, then grew by 4.73% to $4.6 million in 2025.
  • Its Current Deferred Revenue stands at $4.6 million for Q3 2025, versus $4.5 million for Q2 2025 and $3.9 million for Q1 2025.